Gilead Sciences Inc (GILD)

[north40000]

GILD: Some think the work comprising this poster image from MSKCC and PPHM/CDMO, presented at AACR 2017 last April, may be in GILD's future with respect to potentially improving safety of the commercial FDA-approved GILD/KITE CAR-T hematologic and/or solid tumor treatment.

POSTER #1651 IMAGE: http://www.peregrineinc.com/images/stories/pdfs/aacr2017hirschhorn.pdf

"PS targeting decreases tumor-induced immunosuppression. Transferred antimelanoma CD4+ T cells migrate to tumors and promote tumor regression without off-target side effects.
• PS targeting is a desirable strategy that can improve the potency of anti-tumor strategies with known clinical off-target effects such as adoptive T cell transfer.
• PS targeting can be combined with CAR T cells to enhance anti-tumor potential. "

We attended Dr. Wolchok's recent lecture presentation in Baltimore last December at Johns Hopkins Adams Hall[~200 people in auditorium]. His topic was the current state of immuno-oncology therapy. We specifically wanted to hear what he might say in amplification of what he and I discussed at AACR 2017 in Washington, D.C. wrt the above poster. He did discuss the safety aspects of the CAR-T therapies of NVS, JUNO, and GILD/KITE, with the general observation that further work was necessary and ongoing to improve safety to mitigate unpredictable "cytokine storms."

In a Q&A after his lecture, I asked what MSKCC/Ludwig had done to implement the many posters of MSKCC/PPHM appearing at 2016 SITC, 2017 AACR and ASCO, and 2017 SITC wrt clinical trials in humans. I specifically mentioned the above poster. He replied[my paraphrase] "we have prepared a design for a clinical trial." In response to my next question about how that design would be carried out, Dr. Wolchok said "that depends on the company". Because of mutual time constraints, I did not have an opportunity to follow-up with questions to identify either 1)the trial indication or 2) the "company".

Bottom line: Recent events and PRs from PPHM[ongoing prior to 12/2017] evidence a marked change in focus of that company. Its former CEO and BOD are now gone, and a new BOD is in place with the announced intention of monetizing the PPHM assets by way of license or sale. The new company begins trading as CDMO 1/08/2018. Its next ASM is 1/18/2018.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137447228